Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $1.1 billion.

  • Catalyst Pharmaceuticals' Liabilities and Shareholders Equity rose 3621.61% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year increase of 4580.22%. This contributed to the annual value of $851.4 million for FY2024, which is 8110.73% up from last year.
  • Catalyst Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.1 billion in Q3 2025, which was up 3621.61% from $971.9 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $1.1 billion during Q3 2025, and its lowest value of $197.2 million during Q1 2021.
  • In the last 5 years, Catalyst Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $413.2 million in 2023 and averaged $512.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 2362.0% in 2021, then skyrocketed by 8683.19% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Liabilities and Shareholders Equity stood at $237.8 million in 2021, then soared by 57.97% to $375.6 million in 2022, then increased by 25.15% to $470.1 million in 2023, then surged by 81.11% to $851.4 million in 2024, then increased by 23.51% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.1 billion for Q3 2025, versus $971.9 million for Q2 2025 and $908.9 million for Q1 2025.